All In Biotech

NDA 205750 · Mirum

Cholbam

Cholic Acid · Oral · Bile Acid

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Mar 17, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

183

45 Phase 3, 17 recruiting

FAERS reports

403

190 serious, 72 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 26, 2026.

CHOLBAM is a bile acid indicated for: • Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) • Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ). 1.1 Bile Acid Synthesis Disorders Due to Single Enzyme Defects CHOLBAM is indicated for the treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). 1.2. Peroxisomal Disorders Including Zellweger Spectrum Disorders CHOLBAM is indicated for adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. 1.3. Limitations of Use The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established.

Mechanism: Cholic acid is a primary bile acid synthesized from cholesterol in the liver. In bile acid synthesis disorders due to SEDs in the biosynthetic pathway, and in PDs including Zellweger spectrum disorders, deficiency of primary bile acids leads to unregulated accumulation of intermediate bile acids and cholestasis. Bile acids facilitate fat digestion and absorption by forming mixed micelles and facilitate absorption of fat-soluble vitamins in the intestine. Endogenous bile acids including cholic acid enhance bile flow and provide the physiologic feedback inhibition of bile acid synthesis. The...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 17, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelLetter
2 products under this application
  • CHOLBAM · CHOLIC ACID 50MG · CAPSULE, ORAL · Prescription
  • CHOLBAM · CHOLIC ACID 250MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cholic Acid" as an intervention, any sponsor and status, largest first.

All 183 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea58
  • death40
  • vomiting29
  • pyrexia21
  • seizure20
  • constipation19
  • aspartate aminotransferase increased18
  • alanine aminotransferase increased17
  • disease progression16
  • abdominal pain13
  • cough13
  • nasopharyngitis13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20153
201620
201718
201840
201943
202047
202139
202231
2023115
202428
20259
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cholbam (Cholic Acid)

2024 spending

$5.9M

Beneficiaries

n/a

78 claims

Per beneficiary

n/a

$849.01 per unit

View as table
YearSpending
2020$2,701,830
2021$3,358,341
2022$3,638,799
2023$4,476,517
2024$5,938,533

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 96 on PubMed

Sponsor: Mirum

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.